MO - Altria Group, Inc.

NYSE - NYSE Delayed Price. Currency in USD
54.71
-0.11 (-0.20%)
At close: 4:00PM EDT

52.20 -2.48 (-4.54%)
Pre-Market: 8:10AM EDT

Stock chart is not supported by your current browser
Previous Close54.82
Open54.56
Bid53.30 x 1800
Ask52.20 x 1400
Day's Range54.36 - 55.03
52 Week Range42.40 - 66.04
Volume8,576,803
Avg. Volume11,079,914
Market Cap102.329B
Beta (3Y Monthly)0.25
PE Ratio (TTM)14.87
EPS (TTM)3.68
Earnings DateApr 25, 2019
Forward Dividend & Yield3.20 (5.57%)
Ex-Dividend Date2019-03-22
1y Target Est59.07
Trade prices are not sourced from all markets
  • TheStreet.com10 minutes ago

    Altria Shares Fall After Tobacco Maker Misses Earnings Estimates

    "As expected, Altria's first quarter adjusted diluted EPS declined in the mid-single digit range as we incurred higher interest expense as a result of our recently issued debt, without the full benefit of savings from our cost reduction program, which began to ramp up at the end of the quarter," said Howard Willard, Altria's chairman and CEO.

  • Associated Press33 minutes ago

    Altria: 1Q Earnings Snapshot

    Altria Group on Thursday reported first quarter profit of $1.12 billion. On a per-share basis, the Richmond, Virginia-based company said it had net income of 60 cents. Earnings, adjusted for non-recurring ...

  • CNBC46 minutes ago

    Altria's cannabis investment eats into first-quarter earnings, drives profit down 41%. Shares slide

    Altria shares slid more than 5% after the company missed first-quarter earnings, revenue expectations.

  • MarketWatch52 minutes ago

    Altria's stock drops after earnings, revenue fall more than expected

    Shares of Altria Group Inc. dropped 2.6% in premarket trade Thursday, after the tobacco company reported first-quarter earnings and revenue that fell short of expectations. Net income fell to $1.12 billion, or 60 cents a share, from $1.89 billion, or $1.00 a share, in the year-ago period. Excluding non-recurring items, adjusted EPS fell 5.3% to 90 cents, below the FactSet consensus of 92 cents. Net revenue fell 7.9% to $5.63 billion, below the FactSet consensus of $5.97 billion. Smokeable products revenue fell 8.8% to $4.94 billion, as cigarette volume fell 14.3% and Marlboro volume fell 13.5%. Smokeless revenue rose 2.9% to $540 million, while shipment volume fell 2.2%. Altria affirmed its 2019 adjusted EPS outlook of $4.15 to $4.27, which surrounds the FactSet consensus of $4.19. The stock has gained 11% year to date through Wednesday, while the S&P 500 has climbed 17%.

  • Business Wire1 hour ago

    Altria Reports 2019 First-Quarter Results; Reaffirms 2019 Full-Year Earnings Guidance

    Altria Group, Inc. today announces its 2019 first-quarter business results and reaffirms its guidance for 2019 full-year adjusted diluted earnings per share .

  • Investing.com5 hours ago

    Altria Earnings, Revenue Miss in Q1

    Investing.com - Altria (NYSE:MO) reported first quarter earnings that missed analysts' expectations on Thursday and revenue that fell short of forecasts.

  • TheStreet.com14 hours ago

    Altria Group Expected to Earn 92 Cents a Share

    is expected to report quarterly earnings of 92 cents a share on sales of $4.6 billion before the market opens Apr. 25, based on a FactSet survey of 14 analysts. Altria Group is currently trading at a price-to-forward-earnings ratio of 12.8 based on the 12-month estimates of 17 analysts surveyed by FactSet. Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you.

  • FEMSA (FMX) to Report Q1 Earnings: What's in the Offing?
    Zacks23 hours ago

    FEMSA (FMX) to Report Q1 Earnings: What's in the Offing?

    FEMSA's (FMX) results for first-quarter 2019 may continue to bear impacts of soft margins and higher costs. However, the company's growth efforts may bring some relief.

  • Should You Buy Altria (MO) Ahead of Earnings?
    Zacksyesterday

    Should You Buy Altria (MO) Ahead of Earnings?

    Altria (MO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Barrons.comyesterday

    Altria Reports Earnings Tomorrow. Here’s What to Expect.

    Altria Group, the U.S.-focused tobacco firm whose dominant brand is Marlboro, has been facing declining sales.

  • 2 Marijuana Stocks With Rapidly Declining Short Interest
    Motley Foolyesterday

    2 Marijuana Stocks With Rapidly Declining Short Interest

    Have pessimists had a change of heart, or is this simply profit-taking?

  • Barrons.com2 days ago

    Famed Value Investor David Winters Is Shutting Down His Wintergreen Fund

    The once-hot deep-value investor wasn’t able to recover from a 10-plus-year stretch during which beaten-up stocks also struggled.

  • Analysts’ Recommendations for Altria before Its Q1 Results
    Market Realist2 days ago

    Analysts’ Recommendations for Altria before Its Q1 Results

    What’s Expected for Altria’s First-Quarter Earnings(Continued from Prior Part)Analysts’ recommendations Of the 17 analysts covering Altria Group (MO), 47.1% recommend “buy,” 35.3% recommend “hold,” and 17.6%

  • Why Analysts Expect Altria’s EPS to Fall in Q1 2019
    Market Realist3 days ago

    Why Analysts Expect Altria’s EPS to Fall in Q1 2019

    What’s Expected for Altria’s First-Quarter Earnings(Continued from Prior Part)Analysts’ expectations In the first quarter, analysts project Altria Group’s (MO) adjusted EPS to fall 2.9% YoY (year-over-year) to $0.92 from $0.95, dragged down

  • What Analysts Expect for Altria’s First-Quarter Revenue
    Market Realist3 days ago

    What Analysts Expect for Altria’s First-Quarter Revenue

    What’s Expected for Altria’s First-Quarter Earnings(Continued from Prior Part)Analysts’ expectationsIn the first quarter, analysts expect Altria Group’s (MO) to fall 1.7% YoY (year-over-year) to $4.59 billion from $4.67 billion. During the

  • Could Altria’s Q1 2019 Results Boost Its Stock Price?
    Market Realist3 days ago

    Could Altria’s Q1 2019 Results Boost Its Stock Price?

    What’s Expected for Altria’s First-Quarter EarningsStock performanceAltria Group (MO) is set to report its first-quarter earnings on April 25. As of April 18, Altria stock was trading at $54.37, 13.7% higher than when it announced its

  • Factors Likely to Shape Colgate's (CL) Q1 Earnings Outcome
    Zacks3 days ago

    Factors Likely to Shape Colgate's (CL) Q1 Earnings Outcome

    Colgate's (CL) growth efforts make us confident that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.

  • Can Boston Beer (SAM) Beat Q1 Earnings Estimates Despite Odds?
    Zacks3 days ago

    Can Boston Beer (SAM) Beat Q1 Earnings Estimates Despite Odds?

    Boston Beer's (SAM) first-quarter results are likely to reap benefits of the ongoing strength in shipments and depletions. However, soft Samuel Adams brand performance and higher costs remain woes.

  • Financial Times3 days ago

    Juul believes deal with Altria will help hasten demise of tobacco

    “We’ve got the biggest manufacturer of cigarettes in America to hasten their own decline,” said Dan Thomson, managing director of Juul UK. , more than doubled the two-year-old company’s valuation at its previous funding round last summer.

  • The cannabis industry is poised for its biggest 420 yet
    Yahoo Finance6 days ago

    The cannabis industry is poised for its biggest 420 yet

    The “Black Friday” for Cannabis is expected to be bigger than ever this year.

  • If You Can Tolerate Risk, Hexo Stock Is a Buy
    InvestorPlace7 days ago

    If You Can Tolerate Risk, Hexo Stock Is a Buy

    Ah, the magic of analyst ratings! After a tough month in April, cannabis firm Hexo (NYSEAmerican:HEXO) suddenly reversed course after Bank of America analyst Christopher Carey initiated coverage. Sizing up the risk and reward profile, Carey assigned a "buy" rating on Hexo stock with a $10 price target.Source: Shutterstock The news couldn't have come at a better time. While cannabis stocks offer tremendous upside because they essentially materialize an industry that previously never existed, they're also incredibly volatile. Because this is an unprecedented sector, many investors are unsure how to approach a company like HEXO.As such, I mentioned earlier that I liked Hexo stock, even compared to relative heavyweight Aurora Cannabis (NYSE:ACB). Unfortunately, the aforementioned volatility in cannabis stocks disproportionately impacted HEXO, sending my recommendation toward a quick grave. But thanks to Carey, this bad boy gained nearly 12% on Wednesday.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy for Spring Season Growth Of course, by the time that you're reading this, this dramatic burst in Hexo stock is in the past. Do newcomers still have a chance in riding this promising, but wild bull? Underappreciated Elements Support Hexo StockThe best way I can characterize Hexo stock is as a diamond in the rough. I believe the organization has the right components in place to make a solid run. However, the credibility issues that stymie virtually all cannabis stocks will pressure HEXO. At the end of the day, it comes down to your risk tolerance.But if you're willing to take that leap, Carey argues that this weed play deserves your attention. Primarily, HEXO stock is undervalued relative to its peers. Of course, in the marijuana sector, "undervalued" is an extremely relative term. That said, many cannabis stocks have hit nosebleed levels. Therefore, HEXO at least on paper provides some assurance of future room for growth.Next, the BofA analyst mentioned that Hexo stock is levered toward a "de-risked" Canadian cannabis market. Although I wouldn't use that term specifically, I see his point. Our northern neighbors paved the way for other western and developed nations to adopt tolerant policies. While this broader dynamic is building out, management has time to hone its craft.Finally, Carey mentioned "value-add partnerships" that go beyond the scope of Hexo's existent relationship with Molson Coors Brewing (NYSE:TAP). I agree. Cannabis stocks can branch out into subsegments of the broader categories of recreational and medicinal usage. However, let's not gloss over the Molson partnership as it holds a significant key for growth.Naturally, the idea here is for Hexo and Molson to developed cannabidiol (CBD)-infused drinks. Now, CBD itself is a tailwind for the industry as it offers non-psychoactive exposure to the cannabis plant. In other words, it's a lot easier to introduce people to weed through a drink rather than a joint. Upgrade Suggests Rising Credibility for Cannabis StocksIndeed, Hexo's Molson partnership has advantages over an expected synergy like Cronos Group (NASDAQ:CRON) and Altria Group (NYSE:MO). I don't think I can ever get my parents to smoke marijuana. But to drink it in a form that won't get them stoned? That's infinitely more palatable and more socially acceptable.Invariably, that had to enter BofA's thinking process when deciding to go bullish on Hexo stock. But just the fact that the big bank is even considering cannabis stocks is a major sign. It gives the industry significant credibility, and it suggests a very viable environment in the future.While we here in the U.S. have also warmed to varying degrees of legalization, most banks won't finance cannabis-related businesses. Why? Because it comes down to that nasty roadblock called Schedule I. Despite individual state laws, cannabis falls under strict federal guidelines.Sure, we've made progress in this department, too. For instance, the 2018 farm bill won consensus at a time when bipartisanship no longer exists. And major conservative figures have more or less voiced support for full legalization.Nevertheless, that Schedule I classification remains on the books for marijuana. Unless the federal government officially extinguishes it, most banks won't touch cannabis stocks. * 5 Dividend Stocks Perfect for Retirees And while BofA isn't necessarily diving into the sector with open arms, it's essentially giving you the green light to do so. Look, Hexo stock is a risky play no matter how you cut it. But if you've got the nerve, I'd read between the lines.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for Spring Season Growth * This Is How You Beat Back a Bear Market * 7 Dental Stocks to Buy That Will Make You Smile Compare Brokers The post If You Can Tolerate Risk, Hexo Stock Is a Buy appeared first on InvestorPlace.

  • McConnell proposes national minimum age of 21 for tobacco
    Associated Press7 days ago

    McConnell proposes national minimum age of 21 for tobacco

    LOUISVILLE, Ky. (AP) — Senate Majority Leader Mitch McConnell said Thursday he plans to introduce legislation to raise the minimum age to buy tobacco products from 18 to 21 nationally, rating the health initiative as one of his top priorities.

  • Altria Hit By Eleventh-Hour Bears After Tobacco Proposal
    Schaeffer's Investment Research7 days ago

    Altria Hit By Eleventh-Hour Bears After Tobacco Proposal

    Mitch McConnell will introduce a bill to raise the minimum age to buy tobacco and e-cigs

  • Philip Morris Stock Fell despite Strong Q1 Results
    Market Realist7 days ago

    Philip Morris Stock Fell despite Strong Q1 Results

    Philip Morris Beat Analysts' ESP and Revenue Expectations in Q1(Continued from Prior Part)Stock performancePhilip Morris International (PM) outperformed analysts’ revenue and EPS expectations in the first quarter. Despite strong first-quarter

  • Barrons.com7 days ago

    Philip Morris Hopes the FDA Will Help Keep Its Rally Alive

    The tobacco giant was trading down, as concerns about potential legislation overshadowed better-than-expected first-quarter results.